Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Abstract: The present disclosure relates to a modified polypeptide having xylanase activity and the use thereof.

Abstract: A method of manufacturing a multilayer electronic component includes forming a stack by stacking a plurality of ceramic green sheets on which conductive patterns are disposed on a support film, cutting the stack in a second direction, perpendicular to a first direction which is a stacking direction of the plurality of ceramic green sheets, cutting the stack in a third direction, perpendicular to the first and second directions, to obtain a plurality of unit chips, separating the unit chip from the support film, arranging the unit chip such that one of side surfaces of the unit chip is in contact with an adhesive tape, and attaching another one of the side surfaces to a ceramic green sheet for a side margin portion, and forming a side margin portion on the another one of side surfaces.

Abstract: A method for or treating respiratory disease according to an embodiment includes administering to a subject in need thereof an extract of Siraitia grosvenorii residuals as an effective component. The extract of Siraitia grosvenorii residuals has, in an animal model having asthma induced by ovalbumin (OVA), an effect of reducing airway hyper-responsiveness, inhibiting inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing Th2 cytokines (IL-4, IL-5, and IL-13) in BALF, reducing inflammation and tissue damage in lung tissues, inhibiting contraction of airway smooth muscle and airway inflammation, an effect of inhibiting expression of IL-13, TARC, TNF-?, IL-17, and MUC5AC, which is a gene encoding mucus protein, in lung tissues, an effect of reducing the level of ovalbumin-specific IgE in blood serum, and an effect of reducing ROS in alveolar cells which is generated in excess amount due to fine dust.

Abstract: A method for treating osteoarthritis according to an embodiment of the present invention includes administering to a subject in need thereof a composition comprising an extract of Alpinia oxyphylla. The extract of Alpinia oxyphylla can reduce the expression of IL-1?, IL-6, TNF-? and COX-2 as an inflammatory factor and also the expression of MMP-9 as a cartilage degeneration-inducing factor, and can heal the cartilage damage, and thus it can be advantageously used as a functional health food composition for prevention or improvement of osteoarthritis or a therapeutic agent for osteoarthritis.

Abstract: The present invention relates to a composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising an extract of Alpinia oxyphylla as an effective ingredient. Because the extract of Alpinia oxyphylla of the present invention can reduce the uric acid amount in blood of an animal model and is derived from natural products, and the raw materials can be easily obtained, it can be widely used in industries that are related to hyperuricemia or metabolic disorders related with hyperuricemia. It can be effectively used for prevention, amelioration, or treatment of gout or gouty arthritis, in particular.

Abstract: The present invention relates to a composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising an extract of Alpinia oxyphylla as an effective ingredient. Because the extract of Alpinia oxyphylla of the present invention can reduce the uric acid amount in blood of an animal model and is derived from natural products, and the raw materials can be easily obtained, it can be widely used in industries that are related to hyperuricemia or metabolic disorders related with hyperuricemia. It can be effectively used for prevention, amelioration, or treatment of gout or gouty arthritis, in particular.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotriene, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotrien, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotrien, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.

Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotrien, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatement of atopic dermitatis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermitatis.

Abstract: A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Abstract: The present invention relates to (a) variable regions of heavy and light chains of an antibody specific to a surface antigen in sporozoite of Eimeria spp.; (b) a recombinant scFV (single chain variable fragment) antibody prepared using the variable regions; (c) a method for preparing a recombinant scFv antibody; and (d) an expression vector for expressing a recombinant scFv antibody.

Abstract: The present invention relates to (a) variable regions of heavy and light chains of an antibody specific to a surface antigen in sporozoite of Eimeria spp.; (b) a recombinant scFV (single chain variable fragment) antibody prepared using the variable regions; (c) a method for preparing a recombinant scFv antibody; and (d) an expression vector for expressing a recombinant scFv antibody.